Cara Therapeutics Announces Appointment of Joseph Stauffer,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer

SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the appointment of Joseph Stauffer, D.O., as Chief Medical Officer, effective immediately. Dr. Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.

"We are pleased to have Joe join the Cara development team," said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "His successful track record in advancing novel therapeutics through clinical development, regulatory approval and commercial launch will benefit Cara well as we advance I.V. CR845 into Phase 3 registration trials for acute pain and continue development of an oral tablet formulation of CR845 for both acute and chronic pain indications."

Dr. Stauffer brings to Cara more than 15 years of pain development and regulatory experience having served as Chief Medical Officer at numerous specialty pharmaceutical companies including Ikaria, Inc. and Alpharma. While at Alpharma, prior to the company's acquisition by King Pharmaceuticals, he led the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the U.S. Food and Drug Administration (FDA). Prior to getting his industry start as the Global Medical Director for Pain Therapeutics at Abbott Laboratories, Dr. Stauffer served as a Medical Review Officer in the FDA's Anti-inflammatory and Analgesic Division of the Center for Drug Evaluation and Research, where he reviewed regulatory filings for a variety of pain and anti-inflammatory compounds. Dr. Stauffer has also been a founding member of several FDA, industry and academic working groups including the Analgesic Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) and the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT).

"I am pleased to be joining Cara at this exciting time in the development of CR845," said Dr. Stauffer. "There is a tremendous unmet need for new approaches to treating pain, without the common opioid side effects and, more importantly, the potential for abuse. It's clear from the clinical data generated to date, including the recently reported human abuse liability results, that CR845 possesses significant potential to change our approach to managing pain, and reduce the need for traditional opioids and the risks they present."

Dr. Stauffer graduated from the Philadelphia College of Osteopathic Medicine and completed his residency in Anesthesiology & Critical Care Medicine at the Johns Hopkins University Hospital. He maintains an appointment as part-time Assistant Professor at the Johns Hopkins University School of Medicine. Dr. Stauffer is a veteran of the U.S. Navy, honorably discharged as a Lieutenant Commander after serving eight years as a Naval Medical Officer. In addition, he holds an M.B.A. as a joint degree (TRIUM) granted by New York University's Stern School of Business, London School of Economics and Political Science and HEC (Hautes Etudes Commerciales) School of Management in Paris.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 89

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 121

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 186

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Tech Boosts Leadership with Mike Watkinson's Appointment

Updated Category News Views 156

Future Tech Welcomes New CRO to Boost Revenue Strategy Future Tech Enterprise, Inc., a reputable provider of technology solutions, has recently appointed Mike Watkinson as its new Chief Revenue Officer (CRO). In this role, he will be responsible for driving global revenue growth and improving sales strategies for the company. This appointment follows a recent expansion of...

Continue Reading
Supporting Careers of Migraine Sufferers: AbbVie Contest Open

Updated Category News Views 250

AbbVie Launches the Second Annual Career Catalyst Award for Migraine Sufferers AbbVie has opened the entries for the second annual AbbVie Migraine Career Catalyst Award™ contest, offering significant financial assistance to help winners achieve their career aspirations. This initiative is designed to empower individuals living with migraine in their professional...

Continue Reading
Shane Neil Joins Axis Insurance as Senior VP for Eastern Canada

Updated Category News Views 116

So, Axis Insurance shook things up back when they named Shane Neil as their Senior Vice President of Corporate Development for Eastern Canada. This guy's got over 20 years in the insurance game, having kicked off his career at Chubb and moving through some heavyweight roles since then. Traders were eyeing this appointment, knowing that big names can mean bigger moves in...

Continue Reading
Water Ways Technologies Reports Q2 2024 Financial Insights

Updated Category News Views 74

Water Ways Technologies Inc. Reports Q2 2024 Financial Results Water Ways Technologies Inc. (TSXV: WWT) has released its financial results for the second quarter of 2024. As a prominent provider of agricultural technology based in Israel, the company focuses on improving water irrigation solutions and is dedicated to fostering innovation in the agriculture industry....

Continue Reading
Celebrating Technological Excellence: Mats Karlsson's Acclaimed Achievement

Updated Category News Views 116

Icomera Honors CTO Mats Karlsson with the Polhem Prize 2025 Icomera is thrilled to announce that its Chief Technology Officer, Mats Karlsson, has been awarded the Polhem Prize 2025. This esteemed recognition is one of Sweden's highest honors for outstanding contributions to technological innovation, presented by the Swedish Association of Graduate Engineers. The...

Continue Reading